Image Fusion Articles

To present and validate a new technique for biobanking fresh-frozen prostate cancer tissue based on MRI-transrectal ultrasound fusion biopsy.

From August 2014 to August 2016, patients with elevated levels of PSA and at least one suspicious lesion on MRI were invited to this study.

in men with suspicion of prostate cancer (PCa), the standard for cancer detection is trans-rectal ultrasound guided (TRUS) 10-12-core systematic biopsy (SB). Performing a targeted biopsy (TB) only strategy, using MRI-TRUS image registration, is gaining in popularity.

PURPOSE - To guide the surgeon during laparoscopic or robot-assisted radical prostatectomy, an innovative laparoscopic/ultrasound fusion platform was developed, using a motorized 3D-transurethral ultrasound (TUUS) probe.

In the recent years, prostate cancer was the most commonly diagnosed cancer in men. Currently secure diagnosis confirmation is done by a transrectal biopsy and following histopathological examination.

The use of software-based magnetic resonance-transrectal ultrasound fusion to deliver focal therapy may increase the precision of treatment. This is a prospective development study assessing the feasibility of Magnetic resonance imaging-transrectal ultrasound (MRI-TRUS) fusion focal cryotherapy.

Multiparametric magnetic resonance imaging (mpMRI) and MRI fusion targeted biopsy (FTB) detect significant prostate cancer (sPCa) more accurately than conventional biopsies alone.

To evaluate the detection accuracy of mpMRI and FTB on radical prostatectomy (RP) specimen.

To evaluate the influence of PSA-D on positive (PPV) and negative (NPV) predictive values of mpMRI to detect GS ≥7 cancer in a repeat biopsy setting.

Retrospective study of 514 men with previous prostate biopsy showing no or GS 6 cancer.

Magnetic resonance imaging/ultrasound-guided fusion biopsy (FBx) is more accurate at detecting clinically significant prostate cancer than conventional transrectal ultrasound-guided systematic biopsy.